Mark Vishnepolsky
Kidney Associates(US)DaVita Clinical Research (United States)(US)
Publications by Year
Research Areas
Renal Diseases and Glomerulopathies, Systemic Sclerosis and Related Diseases, SARS-CoV-2 and COVID-19 Research, Monoclonal and Polyclonal Antibodies Research, COVID-19 Clinical Research Studies
Most-Cited Works
- → Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center(2009)353 cited
- → WCN23-1126 ATRASENTAN FOR THE TREATMENT OF IGA NEPHROPATHY: INTERIM RESULTS OF THE AFFINITY STUDY(2023)10 cited
- → Atrasentan for the Treatment of IgA Nephropathy: Interim Results From the AFFINITY Study(2022)3 cited
- → WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)(2025)1 cited
- → P-1960. Safety and Pharmacokinetics of Long-acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent after Repeat Dosing: Results from the PROVENT Substudy(2025)1 cited
- → Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study(2026)
- → A phase 3b, multicenter, open‐label, single‐arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations(2023)
- → AFFINITY Study: 1-Year Results of Atrasentan in IgA Nephropathy(2024)